Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00264602 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Dec 2023 to Dec 1, 2029v28
  2. Study completion date: Nov 2020 to Dec 2023v27
  3. Study completion date: Nov 2019 to Nov 2020v26
  4. Study sites: 3 to 4
    • Study completion date: Feb 2019 to Nov 2019
    • Collaborators: 2 to 3
    v25
  5. Study completion date: Jan 2019 to Feb 2019v24
Show 22 earlier versionsHide 22 earlier versions
  1. Primary completion date changed from estimate of Jan 2019 to Sep 1, 2017
    • Start date: Jan 2009 to Feb 18, 2009
    v23
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 114 to confirmed 57
    • Site details revised at 3 of 3 sites
    v22
  3. Interventions: Near Infrared Imaging (Procedure) to Near Infrared Imaging (Drug)
    • Study arms: 0 to 1
    v21
  4. Primary completion date: Jan 2018 to Jan 2019v20
  5. Primary completion date: Sep 2015 to Jan 2018
    • Study completion date: Jan 2016 to Jan 2019
    v19
  6. Primary completion date: Sep 2013 to Sep 2015
    • Study completion date: Jan 2015 to Jan 2016
    v18
  7. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised at 3 of 3 sites
    v17
  8. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v16
  9. Phase: Phase 1/2 to Phase 1
    • Primary completion date: Jan 2013 to Sep 2013
    v15
  10. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised at 3 of 3 sites
    v14
  11. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v13
  12. 2 versions Re-verified since May 16, 2011, no change to tracked fieldsv11-v12
  13. Eligibility criteria shortened, about 8 wordsv10
  14. Re-verified, no change to tracked fieldsv9
  15. Trial status: Not Yet Recruiting to Recruitingv8 Show 4 more changesShow less
    • Primary completion date: Nov 2011 to Jan 2013
    • Start date: Nov 2008 to Jan 2009
    • Study completion date: Nov 2011 to Jan 2015
    • Site details revised at 3 of 3 sites
  16. Primary and study completion dates: Feb 2011 to Nov 2011
    • Start date: Feb 2008 to Nov 2008
    v7
  17. Primary and study completion dates: Feb 2011
    • Start date: Jan 2008 to Feb 2008
    v6
  18. Start date: Jan 2007 to Jan 2008
    • Trial status: Recruiting to Not Yet Recruiting
    • Site details revised at 3 of 3 sites
    v5
  19. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 3 of 3 sites
    v4
  20. Start date: Dec 2005 to Jan 2007
    • Trial status: Recruiting to Not Yet Recruiting
    • Site details revised at 3 of 3 sites
    v3
  21. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary purpose of this study is to determine if we can identify the first lymph node that drains from the tumor, and thus would be the most likely site for metastatic disease, and remove it for analysis to improve the ability to detect tumor in this node and to remove this additional site that potentially contains tumor cells.
Trial Details
NCT Number NCT00264602
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Massachusetts General Hospital
Conditions
(from sponsor)		 Lung Cancer
Related terms Lung Neoplasms
Enrollment 57 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov